SeaStar Medical Holding Corp was originally incorporated in Delaware on June 6, 2007 under the name Nephrion, Inc. On August 3, 2007, the company changed its name to CytoPherx Corporation. On June 19, 2019, in a merger transaction, CytoPherx was renamed SeaStar Medical, a commercialization stage healthcare company focused on developing treatments for critically ill patients facing organ failure. Its core technology, the Selective Cell Adsorption Device, is designed to modulate over-activated immune cells and respond to excessive inflammation. The Company has received regulatory approval for its pediatric therapies and is advancing clinical trials for adult indications. With a number of regulatory approvals that help speed up the R&D process, the agency has established a unique industry position as the only company with approved products for specific pediatric patient groups.
